The number of notified cases of invasive pneumococcal disease (IPD) in the first quarter of 2018 was substantially less than the previous quarter, and similar to the first quarter of 2017. Following the July 2011 replacement of the 7-valent pneumococcal conjugate vaccine (7vPCV) in the childhood immunisation program with the 13-valent pneumococcal conjugate vaccine (13vPCV), there was an initial relatively rapid decline in disease due to the additional six serotypes covered by the 13vPCV across all age groups, however more recently this decline is no longer evident. Additionally, over this period the number of cases due to the eleven serotypes additionally covered by the 23-valent pneumococcal polysaccharide vaccine (23vPPV) and also those serotypes not covered by any available vaccine has been increasing steadily across all age groups (Figure 1 ).
(n=26), 42% (11/26) were due to a serotype included in the 13vPCV, compared with 52% (23/44) of cases in the previous quarter and 57% (24/42) in the first quarter of 2017 ( Figure 2 ). Of the 11 cases with 13vPCV serotypes in the first quarter of 2018, 9 cases were reported in fully vaccinated children aged less than 5 years and considered to be 13vPCV failures. These 13vPCV failures were due to serotypes 3 (n=8) and 19A (n=1) ( Table 4 ). During this quarter the main serotype affecting children aged less than 5 years age group was serotype 3 (35%; 9/26), which is included in the 13vPCV.
Among Indigenous Australians aged 50 years and over, there were 14 cases of IPD reported this quarter. Of those cases with a reported serotype (n=12), 8 (67%) were due to a serotype included in the 23vPPV, and overall there was no particular serotype dominant ( Figure 3 ). The number of notified cases of IPD in this population group was lower than the number of cases reported in the previous quarter (n=21), and slightly higher than the number reported in the first quarter of 2017 (n=11).
Among non-Indigenous Australians † aged 65 years and over there were 91 cases of IPD reported this quarter. The number of notified cases of IPD in this population group were 38% lower compared to the number of cases reported in the previous quarter (n=147) and higher than the number reported in the first quarter of 2017 (n=83). Of those cases with a reported serotype (n=77), 56% (43/77) were due to a serotype included in the 23vPPV (Figure 4 ). This was less than the proportion in the previous quarter (59%; 83/141) and also the first quarter of 2017 (59%; 48/81). For this quarter, serotypes 3 (n=10), 11A (n=7) and 23A (n=7) were the most common serotypes for this population group. All of these serotypes, except 23A, are included in the 23vPPV.
During this quarter there were 18 deaths attributed to a variety of IPD serotypes. Eight of the cases had a serotype covered by currently available pneumococcal vaccines, 6 were due to non-vaccine serotype, and the serotype of the four remaining cases was not able to be determined. Almost all of the reported deaths (83%; n=15) occurred in non-Indigenous Australians † . The median age of those cases reported to have died this quarter was 64 years (range 0 to 92 years). † Non-Indigenous Australians includes cases reported with an Indigenous status of non-Indigenous, not stated, blank or unknown. Non-vaccine type --3 3 38
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